Metagenomi Therapeutics, Inc. (MGX) stock
MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.63−0.05 (-7.21%)
Close on Nov 17, 2026Market cap $23.84MP/E –Yield –
Metagenomi Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Metagenomi Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$85.49M. For fiscal 2025 it was -$88.89M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$88.89M | – |
| FY2024 | Dec 31, 2024 | -$109.07M | – |
| FY2023 | Dec 31, 2023 | -$91.41M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$19.51M | – |
| Q1 FY2026 | Mar 31, 2026 | -$21.18M | – |
| Q4 FY2025 | Dec 31, 2025 | -$23.55M | – |
| Q3 FY2025 | Sep 30, 2025 | -$21.25M | – |
| Q2 FY2025 | Jun 30, 2025 | -$21.25M | – |
| Q1 FY2025 | Mar 31, 2025 | -$22.84M | – |
| Q4 FY2024 | Dec 31, 2024 | -$26.28M | – |
| Q3 FY2024 | Sep 30, 2024 | -$26.64M | – |
| Q2 FY2024 | Jun 30, 2024 | -$26.31M | – |
| Q1 FY2024 | Mar 31, 2024 | -$29.85M | – |
| Q4 FY2023 | Dec 31, 2023 | -$20.59M | – |
| Q3 FY2023 | Sep 30, 2023 | -$23.73M | – |
| Q2 FY2023 | Jun 30, 2023 | -$26.09M | – |
| Q1 FY2023 | Mar 31, 2023 | -$21.00M | – |
See a number that looks wrong?